Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
The nuclear magnetic resonance solution structure of the mixed disulfide between Escherichia coli glutaredoxin(C14S) and glutathione
A GST was induced in the resistant cultivar but its expression was hardly detectable in susceptible plants, suggesting that this GST may play a significant role in anthracnose resistance (Li et al., 2013)
What matters most is having ongoing support to help them succeed with whichever approach makes sense for them." This is where clinical judgment matters
Together, these presentations reflect continued progress across the elecoglipron clinical program and its potential as a once-daily oral GLP-1 receptor agonist for people living with obesity, overweight, or type 2 diabetes
Animal study results do not automatically translate to humans